Volume 68, Issue 6 pp. 573-584
Original Article

Hospitalisation and mortality among privately insured individuals with COVID-19 in the United States: The role of intellectual disabilities and Neurogenetic disorders

A. Davis

A. Davis

Disability Health Research Center, Johns Hopkins University School of Nursing, Baltimore, MD, USA

Search for more papers by this author
N. Copeland-Linder

N. Copeland-Linder

Psychology Department, Notre Dame of Maryland University, Baltimore, MD, USA

Search for more papers by this author
K. Phuong

K. Phuong

Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, USA

Search for more papers by this author
H. Belcher

H. Belcher

Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Office for Health, Equity, Inclusion, and Diversity, Kennedy Krieger Institute, Baltimore, MD, USA

Search for more papers by this author
K. van Eck

Corresponding Author

K. van Eck

Office for Health, Equity, Inclusion, and Diversity, Kennedy Krieger Institute, Baltimore, MD, USA

Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Correspondence: Dr Kathryn Van Eck, Kennedy Krieger Institute, 716 North Broadway, Baltimore, MD 21205, USA (e-mail: [email protected]).Search for more papers by this author
First published: 19 February 2024

Abstract

Background

Individuals with intellectual disabilities (IDs) and neurogenetic conditions (IDNDs) are at greater risk for comorbidities that may increase adverse outcomes for this population when they have coronavirus disease 2019 (COVID-19). The study aims are to examine the population-level odds of hospitalisation and mortality of privately insured individuals with COVID-19 with and without IDNDs IDs, controlling for sociodemographics and comorbid health conditions.

Methods

This is a retrospective, cross-sectional study of 1174 individuals with IDs and neurogenetic conditions within a population of 752 237 de-identified, privately insured, US patients diagnosed with COVID-19 between February 2020 and September 2020. Odds of hospitalisation and mortality among COVID-19 patients with IDNDs adjusted for demographic characteristics, Health Resources and Services Administration region, states with Affordable Care Act and number of comorbid health conditions were analysed.

Results

Patients with IDNDs overall had higher rates of COVID-19 hospitalisation than those without IDNDs (35.01% vs. 12.65%, P < .0001) and had higher rates of COVID-19 mortality than those without IDNDs (4.94% vs. .88%, P < .0001). Adjusting for sociodemographic factors only, the odds of being hospitalised for COVID-19 associated with IDNDs was 4.05 [95% confidence interval (CI) 3.56–4.61]. Adjusting for sociodemographic factors and comorbidity count, the odds of hospitalisation for COVID-19 associated with IDNDs was 1.42 (95% CI 1.25–1.61). The odds of mortality from COVID-19 for individuals with IDNDs adjusted for sociodemographic factors only was 4.65 (95% CI 3.47–6.24). The odds of mortality from COVID-19 for patients with IDNDs adjusted for sociodemographic factors and comorbidity count was 2.70 (95% CI 2.03–3.60). A major finding of the study was that even when considering the different demographic structure and generally higher disease burden of patients with IDNDs, having a IDND was an independent risk factor for increased hospitalisation and mortality compared with patients without IDNDs.

Conclusions

Individuals with IDNDs had significantly higher odds of hospitalisation and mortality after adjusting for sociodemographics. Results remained significant with a slight attenuation after adjusting for sociodemographics and comorbidities. Adjustments for comorbidity count demonstrated a dose–response increase in odds of both hospitalisation and mortality, illustrating the cumulative effect of health concerns on COVID-19 outcomes. Together, findings highlight that individuals with IDNDs experience vulnerability for negative COVID-19 health outcomes with implications for access to comprehensive healthcare.

Conflict of Interest

No conflicts of interest have been declared.

Data Availability Statement

The data that produced the findings from this study are available from FAIR Health. Restrictions apply to the availability of these data, given that they were used under license for this study. Please contact FAIR Health regarding access to these data.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.